Trials / Completed
CompletedNCT00859807
A Bioequivalence Study Comparing Camoquin® Suspension (Pfizer) To Flavoquine® Tablets (Sanofi Aventis) In Healthy Subjects
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine bioequivalence of amodiaquine suspension ( Pfizer) and the WHO approved reference product Flavoquine® tablet ( Sanofi Aventis).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Flavoquine®, Camoquin® Suspension | Treatment A 15.3 mL (50 mg/5 mL) AQ suspension single dose. Treatment B (1 x 200 mg tablet Flavoquine® (Sanofi Aventis) single dose. |
| DRUG | Flavoquine®, Camoquin® Suspension | Treatment A 15.3 mL (50 mg/5 mL) AQ suspension single dose. Treatment B (1 x 200 mg tablet Flavoquine® (Sanofi Aventis) single dose. |
Timeline
- Start date
- 2009-05-01
- Primary completion
- 2009-06-01
- Completion
- 2009-06-01
- First posted
- 2009-03-11
- Last updated
- 2010-04-21
Locations
1 site across 1 country: India
Source: ClinicalTrials.gov record NCT00859807. Inclusion in this directory is not an endorsement.